Eli Lilly's Imlunestrant, an oral selective estrogen receptor degrader (SERD), will have its Phase 3 EMBER-3 trial results presented at the San Antonio Breast Cancer Symposium (SABCS).
Drug Development Updates
Stay informed with timely notifications on clinical trials and research advancements.